HBV as a target for CAR or TCR-T cell therapy

Antonio Bertoletti; Anthony Tanoto Tan

doi:10.1016/j.coi.2020.04.003

HBV as a target for CAR or TCR-T cell therapy

Curr Opin Immunol. 2020 Oct:66:35-41. doi: 10.1016/j.coi.2020.04.003. Epub 2020 Apr 30.

Authors

Antonio Bertoletti¹, Anthony Tanoto Tan²

Affiliations

¹ Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore; Singapore Immunology Network (SigN), Agency of Science Technology and Research (ASTAR), Singapore. Electronic address: antonio@duke-nus.edu.sg.
² Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore.

PMID: 32361634
DOI: 10.1016/j.coi.2020.04.003

Abstract

Engineering HBV-specific T cells utilizing a chimeric antigen receptor (CAR) or a classical T cell receptor (TCR) provides a well characterized, sizeable and functionally intact population of HBV-specific T cells with identical in vitro functionality to the T cells isolated in patients who resolved acute HBV infection. In this review we present evidences of the virological and immunological features of chronic HBV infection, alone or in combination with Hepatitis Delta that might make it amenable for CAR/TCR-T cells therapy.

Publication types

Review

MeSH terms

Cell- and Tissue-Based Therapy*
Hepatitis B virus / immunology*
Humans
Receptors, Antigen, T-Cell / immunology*
Receptors, Chimeric Antigen / immunology*
T-Lymphocytes / immunology*

Substances

Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen